Mortality markers in nosocomial Klebsiella pneumoniae bloodstream infection

Bulent Durdu¹*, Ismail Necati Hakyemez¹, Sibel Bolukcu¹, Gulay Okay¹, Bilge Gultepe² and Turan Aslan¹

Abstract

Purpose: Klebsiella pneumoniae is the most common endogen agent for nosocomial infections. In this study, mortality markers were investigated in patients with nosocomial K. pneumoniae blood stream infection (NKp BSI).

Methods: The characteristics of patients >16 years who had NKp BSI diagnosis by daily active surveillance between January 2012 and January 2016 were retrospectively evaluated. Patients who died until 28th day of the clinical follow up and those who survived until this time were statistically compared in terms of various risk factors.

Results: One hundred ninety patients were included into the study. Mortality rate was 47.9%, carbapenem resistance was 43.2%. Statistical analysis have shown that in presence of post-NKp BSI sepsis, septic shock, following in intensive care unit (ICU), meropenem resistance, kidney failure, NKp BSI secondary to pneumonia, use of invasive instruments such as central venous catheter (CVC), urinary catheter (UC) and mechanical ventilator (MV), colostomy, transfusion and hemodialysis mortality was significantly higher. In patients admitted into the hospital for neurological disorders, pancreaticobiliary tract (PBT) diseases and patients who have undergone endoscopic retrograde cholangiopancreatography (ERCP) and patients in whom NKp BSI secondary to PBT infection mortality rate was lower.

Conclusions: Sepsis, septic shock, clinical conditions requiring ICU treatment and meropenem resistance increase mortality rates in NKp BSI significantly. Mortality was higher also in patients with NKp BSI secondary to pneumonia, in kidney failure and when invasive instruments were used. On the other hand, in patients who were admitted to the hospital for neurological disorders and PBT diseases mortality rate was lower.

Background

Currently, due to increase in surgical procedures, intensive use of invasive instruments, immunosuppressive therapy and other similar practices incidence of health care associated infections (HAI) and its significance have increased worldwide (Kaiser et al. 2013; Kontopidou et al. 2014; Alicino et al. 2015). BSI, either HAI or community-acquired are among the most severe life-threatening infections (Alicino et al. 2015). Enterobacteriaceae are among the most important HAI source (Tumbarello et al. 2012). Within enterobacteriaceae family K. pneumoniae is the most common microorganism isolated as a source of infection in HAI (Tumbarello et al. 2012; Ben-David et al. 2012; Pau et al. 2015; Vardakas et al. 2015).

In the last decade, multi drug resistance (MDR) and the increase in incidence of infections due to Gram negative bacilli producing extended spectrum β lactamase (ESBL) led to the intense use of carbapenem. Because of this, Klebsiella pneumoniae (CRKp) resistant to carbapenem was first reported in 1996 and since then the prevalence of carbapenem resistance have reached to life threatening endemic dimensions in various regions particularly among populations exposed to health care (Ben-David et al. 2012; Gomez-Simmonds et al. 2015). Behindhand discovery of novel effective antibiotics relative to increasing bacterial resistance rates pose difficulty in treating infections and increases mortality rates (Chen et al. 2012). In studies investigating NKp BSI outcomes crude mortality rate was reported at a high range between 23 and 69% (Kontopidou et al. 2014; Tumbarello et al. 2012; Ben-David et al. 2012; Pau et al. 2015; Vardakas et al. 2015; van Duin et al. 2014; Hoxha et al. 2016; Ulu et al. 2015; Kang et al. 2006; Daikos et al. 2014; Correa et al. 2014).
Structure of nosocomial infections is dynamic and complex and usually includes multiple variables negatively affecting clinical outcome. Furthermore, in the initial period of this infection there are additional uncertainties in terms of type of the causative microorganisms and antibiotic susceptibility. Thus, empirical antibiotic therapy is the most critical step in the initial period for combating with the infection. Minimum 2–3 days needed to assess the effectiveness of the antibiotic and to resolve uncertainties about the type of microorganisms further increases the importance of this critical step.

The increasing incidence of NKp BSI, limited therapeutic options and uncertainties in the initial period of the infection leading to higher mortality rates created a need for studies focusing on detecting risk factors having an impact on survival and investigating the effect of empirical therapy.

Worldwide there are various studies on this subject; however, the clinical studies demonstrating the current condition in our country are scarce. Thus, in our hospital we aimed to detect risk factors effecting mortality rate of patients with NKp BSI and to investigate the effect of empirical antibiotic therapy on clinical outcome.

**Methods**

Patients aged >16 years, who were hospitalized between January 1st, 2012 and January 1st, 2016 with clinical features of BSI, with a period of time >48 h passing after hospitalization, with *K. pneumoniae* growth in at least one hemoculture were evaluated retrospectively. The patient was excluded if BSI was polybacterial, if the patient could not be followed-up or his/her medical data could not be accessed. If *K. pneumoniae* had caused more than one BSI in a patient, the first episode was evaluated.

This study was done at Bezmialem Vakif University Medical School Hospital with 550 beds (Istanbul, Turkey). Daily BSI surveillance was done based on patient and laboratory by infectious diseases specialists and infection control nurses in our hospital. Patient data were recorded manually on surveillance forms prepared by the Ministry of Health.

The demographic data, cause of hospitalization, co-morbidities, risk factors, possible sources of infection, sepsis, development of septic shock, type of surgical intervention, antimicrobial susceptibility and information on initial empirical antibiotic use were obtained from surveillance forms. The dates of hemocultures were obtained from the electronic data system on which patient data were recorded.

Sepsis and septic shock were diagnosed according to guidelines (Vincent et al. 2013). Those patients in whom monitoring was considered to be indicated in the ICU in the first 48 h after obtaining culture samples or those whose monitoring at the ICU were decided to be continued in the first 48 h after diagnosis of BSI were considered as requirement for ICU.

HAI was diagnosed during daily active surveillance according to Centers for Disease Control and Prevention criteria and recorded (Sievert et al. 2013). Possible risk factors were selected in light of the medical literature. ERCP and blood/blood product transfusion were considered as a risk factor if done in the last 5 days before BSI and chemotherapy (CT) if done in the last 3 weeks. Surgical drain, MV, CVC, UC, total parenteral nutrition (TPN), hemodialysis (HD) and colostomy were considered relevant if only their use were initiated before development of BSI and were still continuing at the time of BSI development. Surgical interventions that were done in the month before BSI were classified according to systems and were recorded.

The result of antimicrobial susceptibility was considered as resistant to carbapenem (CpR) if resistance against meropenem or imipenem was present, and considered as susceptible to carbapenem if sensitive to both (CpS).

**Microbiology**

Hemoculture tubes (Becton–Dickinson, USA) sent to the microbiology laboratory of our hospital were put in the BACTEC FX (Becton–Dickinson, USA) device, programmed for an incubation period of 5 days. In samples with positive signals during this period, first a gram staining were done from the bottle, after which incubations were done in blood agar (Salubris, Turkey), EMB agar (Salubris, Turkey) and chocolate agar (Salubris, Turkey) at 37 °C for 18–24 h. The bacteria that had grown were defined with conventional methods and automated systems (VITEK® 2 Compact (BioMérieux, France), and antimicrobial susceptibility results obtained with VITEK-2 were evaluated according to Clinical and Laboratory Standards Institute (CLSI) (2013) criteria. The strains identified with Vitec® 2 Compact (BioMérieux, France) device were also examined with Vitec® MS (MALDI-TOF) (BioMérieux, France) device for identification and confirmation and were found to be *K. pneumoniae*. In this study, *K. pneumoniae* strains that were isolated from the same clinical samples of the same patient, showing similar antimicrobial susceptibility patterns were not evaluated. The MIC values found for colistin were also evaluated according to breakpoint test values of The European Committee on Antimicrobial Susceptibility Testing (EUCAST).

**Statistical analysis**

Data was analyzed using SPSS 13.0 (Chicago, IL, USA). Continuous variables were described as mean ± standard deviation and range. Percentage values were described without decimal. To evaluate risk factors associated with mortality, Pearson χ² test, or Fisher’s exact test for
categorical variables and unpaired Student’s t test for continuous variables were performed. Bivariate logistic regression analysis was conducted to obtain unadjusted hazard ratios and revealed as (Hazard ratio (HR); 95% Confidence interval; P value) NKp BSI in comparison of both survivor and non-survivor groups. Risk factors that reached statistical significance (P < 0.05) using a forward selection process remained in the model. All tests were based on two-tailed tests and p < 0.05 were considered as significant.

Results
Two hundred and two patients were included in this study. Seven patients were excluded as they were referred to other centers due to various causes and could not be followed-up, and five patients were excluded due to isolation of multiple agents. Findings, p values, hazards ratios and confidence intervals are summarized at Tables 1 and 2. One hundred and fourteen patients (59.8%) were males and 76 (40.2%) were females. Age distribution was between 20 and 93 years, and mean age was 62.71 (±16.4) years. The mean age of males was 60.89 (±16.18) years, and 65.42 (±16.46) years in females. The sections that the patients were hospitalized were as follows; 63.2% at the ICU, 21.6% at internal medicine wards, 15.2% in surgical wards. The number of patients who died until the 28th day was 91 (47.9%), and the number of those surviving was 99 (52.1%). When mortality rates were evaluated according to sections, 63.3% died at the ICU, 29.3% died at internal medicine sections and 10.3% died at surgical wards. The mean age of patients that died until the 28th day was 64.91 (±15.54) years and the mean age of those surviving was 60.67 (±14.94) years. The range of hospital stay before development of BSI was 3–122 days, with a mean of 27.82 (±26.85) days in those who died and 20.65 (±19.57) days in those who survived. The time interval after diagnosis of BSI till discharge was between 0 and 193 days, with a mean duration of 12.81 (±10.8) days in those who had died, and 33.15 (±28.62) days in those who survived (Table 1).

The number of patients in whom sepsis developed was 167 (87.9%), and the number of patients with septic shock was 105 (55.3%). Mortality was significantly higher in those in whom sepsis and septic shock had developed. Mortality rates at the 28th day of patients for whom ICU care was indicated in the first 24 h after BSI or in those whose requirement for ICU care continued were significantly higher (Table 1).

Rates of UC, CVC and MV use were 75.1, 70.9 and 66.1%, respectively. Mortality rates were significantly higher in those in whom UC, CVC and MV were used. Mortality rates were significantly higher in patients in whom hemodialysis, colostomy and blood/blood product transfusions were administered, while mortality was lower in patients in whom ERCP was done (Table 1).

The most frequent cause was central line associated BSI (CLABSI) (29.5%), and the second most frequent cause was pneumonia (22.6%) among primary infection sources that cause NKp BSI. Other possible causes include PBT infections (18.4%), primary BSI (10.5%), surgical area infection (SAI) (10%), urinary tract infections (UTI) (6.8%) and soft tissue infections (STI) (2.1%). All of the patients in whom possible BSI source was pneumonia were those that received MV support in the ICU and mortality was significantly high in this group. On the other hand, mortality was lower in patients in whom the possible source was PBT infections. A significant difference was not observed in others (Table 1).

Among diseases that required hospitalization, most prevalent was malignancy (33.7%), followed by acute respiratory failure (25.3%). Other disorders included PBT infections (16.8%), neurological disorders (16.8%), pneumonia (15.8%), acute abdominal pain (11.1%), trauma (9.5%), acute renal failure (ARF) (9.5%), cardiac disorders (8.9%), sepsis (7.4%), UTI (4.2%) and chronic hepatic diseases (3.7%). Mortality was high in patients in whom the cause of hospitalization was ARF, while it was lower in those with PBT infection and neurological disorders. Mortality on the 28th day was high only in the presence of CRF among co-morbidities (Table 1).

43.7% of the patients had undergone surgical intervention before BSI. Types of surgery included gastrointestinal system (GIS) (14.7%), musculoskeletal system (10.5%), central nervous system (CNS) (7.9%), genitourinary system (GUS) (6.8%), PBT and hepatic surgery (6.3%), thoracic surgery (2.1%) and cardiovascular surgery (CVS) (1.1%), in descending order of frequency. A significant association between mortality on the 28th day was not observed in patients who had or had not undergone surgery before BSI. Also, a significant association between type of surgery and mortality on the 28th day was not observed (Table 1).

Resistance rates of 190 K. pneumoniae strains according to CLSI breakpoint values were as follows: tigecycline (TGC) 23.2%, trimethoprim-sulfamethoxazole (TMP-SXT) (39.5%), meropenem (MEM) 41.6%, gentamicin (GM) (46.8%), amikacin (AK) (53.7%), levofloxacin (LEV) (68.4%), ciprofloxacin (CIP) (70.0%), tetracyclin (TE) (73.2%), piperacillin-tazobactam (TZP) (74.2%), cefoperazone-sulbactam (CES) (77.4%), ceftazidim (CAZ) (89.5%), cefepime (FEP) (90.5%), sulbactam-ampicillin (SAM) (92.6%). Although breakpoint values suggested by VITEC II for colistin (CS) was not approved by the US Food and Drug Administration (FDA), 10% resistance was observed, while resistance was not found with EUCAST breakpoint values. When the association of
### Table 1  Clinical variables and relationship with day 28th mortality

| Variable                                | Died (91)         | Living (99)        | P value | HR (CI)           |
|-----------------------------------------|-------------------|--------------------|---------|------------------|
|                                         | N     | %    | N     | %    |                |
| Demographic data                        |       |      |       |      |                 |
| Mean age                                | 64.91 ± 15.54    | 60.67 ± 14.94     | 0.074   |                  |
| Hospital stay before BSI                | 27.82 ± 26.85    | 20.65 ± 19.57     | 0.085   |                  |
| Hospital stay after BSI                 | 12.81 ± 10.8     | 33.15 ± 28.62     | 0.0005  |                  |
| Male sex                                | 56    | 61.5 | 58    | 58.6 | 0.678           |
| Infection complication                  |       |      |       |      |                 |
| Sepsis                                  | 91    | 100  | 76    | 76.8 | 0.0005          |
| Septic shock                            | 81    | 89   | 24    | 24.2 | 0.0005          |
| Need for ICU after infection            | 91    | 100  | 66    | 66.7 | 0.0005          |
| BSI Source                              |       |      |       |      |                 |
| CLABSI                                  | 25    | 27.5 | 31    | 31.3 | 2.61 (1.29–5.29)|
| Pneumonia                               | 29    | 31.9 | 15    | 15.2 | 0.006           |
| Pancreaticobiliary tract                | 8     | 8.8  | 27    | 27.3 | 0.001           |
| Primer BSI                              | 12    | 13.2 | 8     | 8.1  | 0.251           |
| SSI                                     | 10    | 11   | 9     | 9.1  | 0.810           |
| UTI                                     | 6     | 6.6  | 7     | 7.1  | 0.896           |
| YDE                                     | 2     | 2.2  | 2     | 2    | 1.00            |
| Indication of admittance into hospital  |       |      |       |      |                 |
| Malignancy                              | 28    | 30.8 | 36    | 36.4 | 0.415           |
| Acute respiratory failure               | 26    | 28.6 | 22    | 22.2 | 0.314           |
| Pancreaticobiliary tract infection      | 9     | 9.9  | 23    | 23.2 | 0.013           |
| Neurological disorder                   | 9     | 9.9  | 23    | 23.2 | 0.019           |
| Pneumonia                               | 17    | 18.7 | 13    | 13.1 | 0.295           |
| Acute abdomen                           | 11    | 12.1 | 10    | 10.1 | 0.663           |
| Trauma                                  | 8     | 8.8  | 10    | 10.1 | 0.758           |
| Acute renal failure                     | 13    | 14.3 | 5     | 5.1  | 0.028           |
| Cardiac disease                         | 11    | 12.1 | 6     | 6.1  | 0.144           |
| Sepsis                                  | 8     | 8.8  | 6     | 6.1  | 0.422           |
| UTI                                     | 4     | 4.4  | 4     | 4    | 0.903           |
| Chronic live disease                    | 4     | 4.4  | 3     | 3    | 0.618           |
| Co–morbid disease                       |       |      |       |      |                 |
| Hypertension                            | 45    | 49.5 | 50    | 50.5 | 0.885           |
| Malignancy                              | 34    | 37.4 | 43    | 43.4 | 0.394           |
| Diabetes mellitus                       | 27    | 29.7 | 25    | 25.3 | 0.495           |
| Neurological disorder                   | 21    | 23.1 | 27    | 27.3 | 0.506           |
| Coronary artery disease                 | 14    | 15.4 | 26    | 26.3 | 0.064           |
| Chronic liver failure                   | 27    | 29.7 | 11    | 11.1 | 0.001           |
| Cardiac insufficiency                   | 15    | 16.5 | 15    | 15.2 | 0.801           |
| Chronic obstructive pulmonary disease   | 10    | 11   | 14    | 14.1 | 0.512           |
| Hepatic failure                         | 5     | 5.5  | 6     | 6.1  | 0.867           |
| Risk factor                             |       |      |       |      |                 |
| Urinary catheter                        | 76    | 83.5 | 66    | 66.7 | 0.007           |
| CVC                                     | 71    | 78   | 63    | 63.6 | 0.029           |
| Mechanic ventilation                    | 69    | 75.8 | 56    | 56.6 | 0.005           |
| Blood and blood product transfusion     | 51    | 56   | 41    | 41.4 | 0.043           |
| Drainage                                | 38    | 41.8 | 34    | 34.3 | 0.293           |
| Total parenteral nutrition              | 31    | 34.1 | 28    | 28.3 | 0.390           |
| ERCP                                    | 9     | 9.9  | 25    | 25.3 | 0.005           |

Risk factor
antimicrobial resistance and mortality was examined, mortality was found to be significantly increased in the presence of MEM resistance, while significant changes were not observed in the presence of resistance to other antimicrobials (Table 2). CR was detected in 82 patients (43.2%). Mortality rate was 56.1% in the presence of CR, and 41.7% in the presence CS.

The rate of initiation of appropriate empirical antimicrobial treatment was 55.2% in general study population, while 53.8% in patients who had died and 57.6% in those surviving. A statistically significant difference was not observed between mortality rates of patients who received or did not receive appropriate empirical therapy (Table 1).

### Table 1  continued

| Variable                              | Died (91) | Living (99) | P value | HR (CI)       |
|---------------------------------------|-----------|-------------|---------|---------------|
|                                       | N         | %           | N       | %             |               |
| Hemodialysis                          | 20        | 22          | 9       | 9.1           | 0.013 2.81 (1.2–6.56) |
| Chemotherapy                          | 16        | 17.6        | 9       | 9.1           | 0.082          |
| Colostomy                             | 12        | 13.2        | 2       | 2             | 0.002 7.36 (1.6–33.89) |
| Previous surgical procedure           |           |             |         |               |                |
| Gastrointestinal system               | 14        | 15.4        | 14      | 14.1          | 0.809          |
| Musculo-skeletal system               | 10        | 11          | 10      | 10.1          | 0.842          |
| Central nervous system                | 7         | 7.7         | 8       | 8.1           | 0.921          |
| Genitourinary system                  | 4         | 4.4         | 9       | 9.1           | 0.256          |
| Bile ducts, liver and pancreas       | 8         | 8.8         | 4       | 4             | 0.236          |
| Thorax surgery                        | 4         | 4.4         | 0       | 0             | 1.00           |
| Cardiovascular surgery                | 1         | 1.1         | 1       | 1             | 0.051          |
| Operation                             | 41        | 45.1        | 42      | 42.4          | 0.715          |
| Appropriate empirical antibiotic therapy | 49    | 53.8        | 57      | 57.6          | 0.662          |

BSI bloodstream infection; ICU intensive care units; HR hazard ratio; CI confidence interval; SSI surgical site infection; UTI urinary tract infection; SSTI skin and soft tissue infection; CLABSI central line-associated bloodstream infection; CVC central venous catheter; ERCP endoscopic retrograde cholangiopancreatography

### Table 2  Relationship between antibiotic resistance and mortality

| Antibiotic                           | Died (91) | Living (99) | P value | HR (CI)       |
|---------------------------------------|-----------|-------------|---------|---------------|
|                                       | Susceptible | Susceptible |         |               |
|                                       | N         | %           | N       | %             |               |
| Colistin                              | 91        | 100.0       | 99      | 100.0         | 1.00           |
| Tigecycline                           | 71        | 78.0        | 75      | 75.8          | 0.734          |
| Trimethoprim-sulfametaxazol           | 59        | 64.8        | 56      | 56.6          | 0.299          |
| Meropenem                             | 46        | 50.5        | 65      | 65.7          | 0.035 0.53 (0.29–0.95) |
| Imipenem                              | 46        | 50.5        | 63      | 63.6          | 0.068          |
| Meropenem or imipenem                 | 46        | 50.5        | 63      | 63.6          | 0.067          |
| Gentamicin                            | 44        | 48.4        | 57      | 57.6          | 0.245          |
| Amikacin                              | 40        | 44.0        | 48      | 48.5          | 0.532          |
| Levofloxacin                          | 28        | 30.8        | 32      | 32.3          | 0.876          |
| Ciprofloxacin                         | 25        | 27.5        | 32      | 32.3          | 0.466          |
| Tetracycline                          | 20        | 22.0        | 31      | 31.3          | 0.190          |
| Piperacillin-tazobactam               | 21        | 23.1        | 28      | 28.3          | 0.412          |
| Cefoperazone-sulbactam                | 18        | 19.8        | 25      | 25.3          | 0.391          |
| Cefazidime                            | 8         | 8.8         | 12      | 12.1          | 0.488          |
| Cefepime                              | 7         | 7.7         | 11      | 11.1          | 0.466          |
| Ampicillin-sulbactam                  | 7         | 7.7         | 7       | 7.1           | 1.00           |
Discussion

In our study mortality rate at the 28th day was high with 47.9%. In the literature, reported mortality rate is within the range 23–69% and the highest mortality rates were observed in patients admitted to ICU and in BSI cases where CRKP is the culprit agent (Kontopidou et al. 2014; Tumbarello et al. 2012; Ben-David et al. 2012; Vardakas et al. 2015; van Duin et al. 2014; Hoxha et al. 2016; Ulu et al. 2015; Kang et al. 2006; Daikos et al. 2014; Correa et al. 2013). We concluded that mortality rate was high in our patients, since most of them were admitted to ICU. The studies on this subject are scarce in our country. In a 2012 study investigating *K. pneumoniae* infections in ICUs a similar mortality rate with 48% was reported (Ulu et al. 2015). These high rates have shown that NKp BSI is a global issue requiring an urgent answer.

Sepsis and septic shock was found to be associated with high mortality. In a Korean study septic shock was found to be an independent risk factor in community acquired infections and NKp BSI (Kang et al. 2006). In studies carried out in USA, Greece and Italy mortality was found to be higher in patients developing septic shock after CRKp infection (Tumbarello et al. 2012; Vardakas et al. 2015; Daikos et al. 2014; Capone et al. 2013). Septic shock is a grave clinical condition leading to failure in maintaining vital functions and loss of function. Monitoring of these patients is usually maintained at ICU under intense medical therapy and by using invasive instruments. Thus, these patients are exposed to adverse effects of medical therapy and under risk of complications due to the use of invasive instruments. Furthermore, extreme age and concomitant diseases paving the way for development of sepsis and septic shock make the clinical picture more severe. Unsurprisingly, these negative factors altogether lead to high mortality. Getting care at ICU has been determined as an independent risk factor related with high mortality rate. In a US study ICU was found to be associated with high mortality (Gomez-Simmonds et al. 2015). In a review mortality rate was reported to be higher in patients developing BSI during their stay at ICU (Petrosillo et al. 2013).

In our study, mortality was significantly higher in patients having NKp BSI secondary to pneumonia. Studies reported from USA, Italy, Hong Kong and Korea also include data supporting our results (Pau et al. 2015; Kang et al. 2006; Capone et al. 2013; Qureshi et al. 2012). Qureshi et al. have assumed that high mortality in BSI secondary to pneumonia was due to the higher severity of underlying disease and relative difficulty in controlling the source of infection in pneumonia compared with other sources (Qureshi et al. 2012). In a review use of MV was emphasized as a factor facilitating colonization with resistant *K. pneumoniae* strains and development of infection (Petrosillo et al. 2013). Also, in all of the patients with BSI secondary to pneumonia use of MV in ICU was the case and that may have lead to inadequate control of infection in these patients. Thus, in patients getting MV support at ICU rigorous attention is mandatory to prevent pneumonia in these patients and infection control measures should also be checked. In case pneumonia has occurred, efforts for prevention of more severe infections such as BSI should be spent by way of early, appropriate treatment.

Survival was found to be higher in patients whom probable BSI source is PBT infection. In the reviewed literature there was only one study investigating the relationship between PBT infection and Kp BSI. In this Korean study, survival rate was found to be significantly high in patients having community-acquired Kp BSI or NKp BSI with PBT infection as the probable source of infection. Observed characteristics of patients with PBT infection were less co-morbidity compared to general population, less exposure to invasive instrument use, shorter hospitalization and lower rate of care at ICU. These were considered as the factors leading to higher survival rates. In line with this, survival rate was high also in patients who have undergone ERCP. Obstructions within the PBT may facilitate development of infection. It’s considered that easy passage from the PBT after ERCP performed with minimal invasiveness and use of prophylactic antibiotics may have facilitated infection control and thereby may have increased survival rate.

In patients hospitalized for ARF or in those having CRF as co-morbid disease but hospitalized for another disorder and in patients getting hemodialysis as supportive therapy mortality rate at Day 28 was found to be significantly higher. In various studies presence of significant correlation with renal failure and mortality was emphasized (Vardakas et al. 2015; Qureshi et al. 2012; Corcione et al. 2014; Hussein et al. 2013; Dubrovskaya et al. 2013). In a study performed in USA use of non-optimal doses of nephrotoxic antibiotics such as CS was blamed in the relationship between renal failure and high mortality (Dubrovskaya et al. 2013). The probable requirement of invasive supportive therapies such as hemodialysis which are risk factors for HAI in renal failure, immunosuppressive effects of CRF and inability to use optimal dose of antibiotic eliminated via kidneys may cause high mortality in presence of RF.

Urinary catheter, CVC and MV use was found to be associated with increasing mortality. In various studies reported mortality rates were high in patients exposed to use of these types of invasive instruments (Ben-David et al. 2012; Gomez-Simmonds et al. 2015; Kang et al. 2006; Petrosillo et al. 2013; Hussein et al. 2013). A relationship between use of these invasive instruments and
colonization of these instruments with resistant organisms and development of infection was emphasized in some studies (Ben-David et al. 2012; Kang et al. 2006; Petrosillo et al. 2013). Use of these instruments rather in patients with a severe clinical picture who require care at ICU may also contribute to high mortality rate.

In our study, mortality was significantly high in patients with colostomy. In the reviewed literature there was only one study investigating effect of presence of colostomy on mortality and no significant association was detected (Michalopoulos et al. 2011). The studies were rather focused on the effect of presence of colostomy/PEG on antibiotic resistance. Researchers have concluded that presence of colostomy/PEG didn't cause any change in resistance rates (Liu et al. 2012; Chang et al. 2011; Falahgas et al. 2006). Further studies focused on relationship of this entity and mortality is needed.

In our study there was no significant relationship between type of surgical procedure and mortality. In a study, having a surgical operation within the last one month wasn't found to be significantly related with mortality but the type of surgery wasn't reported (Capone et al. 2013). It’s assumed that pre-op assessment for co-morbid diseases before elective surgical procedures and postponing or cancelling surgical operations in uncontrolled diseases may contribute to lack of high mortality. Also, shorter pre-op and post-op hospital stay may affect natural flora less and this may lower the risk for colonization with resistant microorganisms and risk of infection.

Our findings have shown that, according to EUCAST breakpoint values colistin resistance doesn’t exist in our hospital; however, CR rates was high (43.2%) in accordance with the literature (Alicino et al. 2015; Vardakas et al. 2015; Chen et al. 2012; van Duin et al. 2014; Ulu et al. 2015; Hussein et al. 2013). In a study investigated instrument-related infections developing during 2003–2012 in our country and including all ICUs of 29 hospitals from 10 cities CRKp resistance rate at CLABSI was 6.3% (Leblebicioglu et al. 2014). In two separate studies investigating HAI developing in ICUs during 2009–2011 and 2012 CRKp rate was 22 and 48% respectively (Ulu et al. 2015; Budak et al. 2014). Increasing CRKp incidence over the years are clearly seen in these studies and our CRKp rate is high in line with the data of Candevir et al. which is the closest study to present-time (Ulu et al. 2015). In line with the literature, high CRKp incidence which is a threat in most countries has also grown in our country to a dimension that is posing threat. New studies revealing more clear data and including various regions are needed about this issue.

Contrary to our expectations, there was no significant relationship between appropriate use of empirical antibiotic therapy and survival. Presence of many adverse factors such as co-morbid diseases or negative clinical conditions adversely effecting survival may cancel the positive effects of appropriate use of empirical antibiotic therapy in lowering mortality rates. In similar studies it was reported that conformity of initial therapy with antibiogram test doesn’t lead to a change in survival rate of patients (Ben-David et al. 2012; Pau et al. 2015; Correa et al. 2013; Qureshi et al. 2012).

Our study has some limitations such as its retrospective design which doesn’t permit desired modifications in the design of the study. The antibiotic susceptibility tests were only performed with automated system because microbiology laboratory of our university had a work overload and the personnel were few. Procalditonin and lactate test results were available only for few cases so that we didn't mentioned about them in the paper. Since K. pneumoniae have different resistance profiles we used many different antibiotics or combinations as treatment. The data about the treatment was too excessive so we just mentioned about empirical therapy.

Conclusions

Our study has shown that mortality is high in the presence of post-NKp BSI sepsis, septic shock, ICU treatment, meropenem resistance, NKp BSI secondary to pneumonia, kidney failure as the reason for hospitalization and having renal failure as co-morbid disease. Furthermore, mortality was also high in those requiring MV and hemodialysis as supportive therapy, and in presence of UC, CVC and colostomy. On the other hand, in patients who were admitted to the hospital for neurological disorders, PBT diseases, in those whom PBT infections is considered as the source of BSI and in patients who have undergone ERCP mortality rate was lower. In situations leading to an increase in mortality rates rigorous attention is needed in following the rules for infection control measures, wide-spectrum antibiotics should be preferred in empirical therapy and remedial strategies for future should be adopted.

Abbreviations

NKpBSI: nosocomial K. pneumoniae bloodstream infection; UC: urinary catheter; PBT: pancreaticobiliary tract; HAI: health care associated infections; CT: chemotherapy; TPN: total parenteral nutrition; HD: hemodialysis; BSI: bloodstream infection; ICU: intensive care units; HR: hazard ratio; CI: confidence interval; SSL: surgical site infection; UTR: urinary tract infection; STI: soft tissue infection; CLABSI: central line-associated bloodstream infection; CVC: central venous catheter; ERCP: endoscopic retrograde cholangiopancreatography; CR: carbapenem resistance; CPS: carbapenem susceptible; CLSI: Clinical and Laboratory Standards Institute; EUCAST: The European Committee on Antimicrobial Susceptibility Testing; ARF: acute renal failure; CRF: chronic renal failure; GIS: gastrointestinal system; CNS: central nervous system; GUS: genitourinary system; CVS: cardiovascular surgery; TGC: tigecycline; TMPSXT: trimethoprim-sulfamethoxazole; MEM: meropenem; GM: gentamicin; AK: amikacin; LEV: levofloxacin; CIP: ciprofloxacin; TE: tetracyclin; TZIP: piperacillin-tazobactam; CES: cefoperazone-sulbactam; CAZ: ceftazidim; FEP: ceftazime;
Alicino C, Giacobbe DR, Orsi A, Tassinari F, Trucchi C, Sarteschi G et al (2015) The determination of carbapenem resistance in Escherichia coli and Klebsiella pneumoniae isolates related to nosocomial infections and the evaluation of risk factors. Southeast Asian J Trop Med Public Health 46(1):113–122

Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M et al (2013) High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae blood infection accounts for an excess of mortality. Clin Microbiol Infect 19(1):E32–E30

Chang H, Hsu PC, Yang CC, Kuo AJ, Chia JH, Wu TL et al (2011) Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case–control study. J Microbiol Immunol Infect 44(2):125–130

Chen LF, Anderson DJ, Paterson DL (2012) Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance. Infect Drug Resist 5:133–141. doi:10.2174/MDR.526613

Clinical and Laboratory Standards Institute (2013) Performance standards for antimicrobial susceptibility testing, twenty-third informational supplement, vol 33. Clinical and Laboratory Standards Institute, Wayne, pp 62–64

Corcione S, Cardellino CS, Calcagno A, Fossati L, Costa C, Cavallo R et al (2014) Hematologically associated Klebsiella pneumoniae carbapenemase producing K. pneumoniae bloodstream infection: the time has come. Clin Infect Dis 59(9):221–232. doi:10.1093/cid/ciu294

Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV et al (2013) A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 13:80. doi:10.1186/1471-2334-13-80

Daikos GL, Tsoukis S, Tsouvelakis LS, Anyfantis I, Psichogiou M, Arygropou- lou A et al (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58(4):2322–2328. doi:10.1128/AAC.02166-13

Dubrovičkaia Y, Chen TY, Scipione MR, Esaia D, Phillips MS, Papadopoulos J et al (2013) Risk factors for treatment failure of polymyxin B Monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 57(11):5394–5397. doi:10.1128/Jcm.00510-13

Falgas M, Rafaelidis P, Kasiakou S, Hatzopoulos P, Michalopoulos A (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs colistimero- penem combination therapy for multidrug resistant Gram negative bacterial infections. Clin Microbiol Infect 12(12):1227–1230

Gomez-Simmonds A, Greenman M, Sullivan SB, Tanner JP, Sowash MG, Whit- tier S et al (2015) Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. J Clin Microbiol 53(7):2060–2067. doi:10.1128/jcm.03455-14

Hoˇsa A, Karkl T, Giambi C, Montano C, Sisto A, Bella A et al (2016) Attributional mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012–2013. J Hosp Infect 92(1):61–66

Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I et al (2013) Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteremia caused by Klebsiella pneumoniae. J Hosp Infect 83(4):307–313. doi:10.1016/j.jhin.2012.10.012

Kaiser RM, Castanheira M, Jones RN, Tenover F, Lynfield R (2013) Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007–2009 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 76(3):356–360. doi:10.1016/j.diagmicrobio.2013.03.032

Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim E-C et al (2006) Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 21(8):816–822

Kontopodidou F, Giarmarelou H, Katerelos P, Maragos A, Kiousis I, Trikka-Graph- kos E et al (2014) Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multicentre study on clinical outcome and therapeutic options. Clin Microbiol Infect 20(2):O117–O123. doi:10.1111/1469-0691.12341

Leblebioglu H, Erben N, Rosenthal VO, Atayasi B, Erbay A, Unal S et al (2014) International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003–2012. Ann Clin Microbiol Antimicrob 13(1)

Liu SW, Chang HJ, Chia JH, Kuo AJ, Wu TL, Lee MH (2012) Outcomes and characteristics of etenapenam-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Infect Dis 45(2):113–119

Michalopoulos A, Falagas ME, Karatza DC, Alexandropoulou P, Michalopoulos A, Gregorakos L et al (2011) Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 39(5):396–400

Pau CK, Ma FF, Ip M, You JH (2015) Characteristics and outcomes of Klebsiella pneumoniae bacteremia in Hong Kong. Infect Dis (Lond) 47(5):283–288. doi:10.3109/03655484.2014.985710

Petrosillo N, Giannella M, Lewis R, Viale P (2013) Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 11(2):159–177. doi:10.1586/eri.12.162

Qureshi ZA, Paterson DL, Potoksi BA, Klayko MC, Sandovsky G, Sordillo E et al (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56(4):2108–2113

Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Shinivasan A et al (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34(1):1–14

Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950. doi:10.1093/cid/cis588
Ulu AC, Kurtaran B, Komur S, Kibar F, Cicekdemir HY et al (2015) Risk factors of carbapenem-resistant *Klebsiella pneumoniae* infection: a serious threat in ICUs. Med Sci Monit 21:219–224. doi:10.12659/MSM.892516

van Duijn D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J et al (2014) Surveillance of carbapenem-resistant *Klebsiella pneumoniae*: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 58(7):4035–4041. doi:10.1128/Aac.02636-14

Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E (2015) Characteristics, risk factors and outcomes of carbapenem-resistant *Klebsiella pneumoniae* infections in the intensive care unit. J Infect 70(6):592–599. doi:10.1016/j.jinf.2014.11.003

Vincent JL, Opal SM, Marshall JC, Tracey KJ (2013) Sepsis definitions: time for change. Lancet (Lond) 381(9868):774